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Stimulation with live dengue virus of peripheral blood mononuclear cells from a dengue virus type 4-immune
donor generated virus-specific, serotype-cross-reactive, CD8+, class I-restricted cytotoxic T lymphocytes
(CTL) capable of lysing dengue virus-infected cells and cells pulsed with dengue virus antigens of all four
serotypes. These CTL lysed autologous fibroblasts infected with vaccinia virus-dengue virus recombinant
viruses containing the E gene or several nonstructural dengue virus type 4 genes. These results demonstrate
that both dengue virus structural and nonstructural proteins are targets for the cytotoxic T-cell-mediated
immune response to dengue virus and suggest that serotype-cross-reactive CD8+ CTL may be important
mediators of viral clearance and of virus-induced immunopathology during secondary dengue virus infections.
The severe manifestations of dengue virus infections,
hemorrhage and shock, are most often seen after secondary
infection with a heterologous serotype of dengue virus,
implying a central role for the immune response in the
pathogenesis of dengue hemorrhagic fever (DHF) and den-
gue shock syndrome (DSS). Serotype-cross-reactive anti-
bodies at subneutralizing concentrations form complexes
with virions which bind to monocytes via Fc receptors,
resulting in greater numbers of infected monocytes and high
virus titers in vitro (14, 15). This phenomenon, known as
immune enhancement, probably contributes to the patho-
genesis of DHF-DSS but may be only part of the overall
process. Less is known about the T-cell responses to dengue
virus and its role in the immunity to and pathogenesis of
DHF-DSS.
We have shown that CD4+ T cells from dengue virus-
immune humans and mice proliferate in response to soluble
dengue virus antigens (22, 27). They produce gamma inter-
feron (IFN-y) (22), which up regulates Fc receptor expres-
sion on monocytes (12) and further increases infection by
immune enhancement (19). In addition, we have recently
detected serotype-cross-reactive, CD4+ CD8- cytotoxic T-
lymphocyte (CTL) clones, which are class II restricted and
secrete IFN-y (22a).
It is also important to identify dengue virus-specific,
CD8+, class I-restricted CTL and to define their functions.
Evidence from studies in virus-infected animals indicates a
necessary role for CD8+ virus-specific CTL in recovery
from certain virus infections (6, 23) and for inducing immu-
nopathology (9, 23).
Little is known about CD8+ cells in dengue virus infec-
tions. They do not seem to proliferate in response to soluble
dengue virus antigens (27), and dengue virus-specific, CD8+
CTL have not yet been described. However, T-cell re-
sponses to soluble antigens are usually of the CD4+ variety
(7, 18, 20, 24), probably because of the class II-restricted
nature of soluble antigen processing. CD8+ CTL responses
have been detected to other viruses after stimulation with
live virus (2) or with virus-infected fibroblasts (16). This is
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presumably due to a requirement for intracellular antigen
processing, which appears to be important for optimal anti-
gen presentation in the context of class I molecules (17, 26,
33).
In this report, we describe the proliferation of peripheral
blood mononuclear cells (PBMC) from a dengue virus type
4-immune donor in response to live dengue virus and the
generation of serotype cross-reactive, CD8+, class I-re-
stricted, dengue virus-specific CTL. Using vaccinia virus-
dengue virus recombinant viruses, we show that the E
protein and one or more of the nonstructural proteins are
targets for lysis by these CTL. The results suggest that these
CD8+ serotype cross-reactive CTL may mediate viral clear-
ance and contribute to shock by lysing dengue virus-infected
cells in secondary infections.
MATERIALS AND METHODS
Human PBMC. Blood was obtained from a healthy donor
who had been immunized with an experimental live dengue
virus type 4 vaccine 1 year earlier. The human leukocyte
antigen types of the lymphocytes are A2, 9; B35, 12; Cw4;
DR7, w53; and DQw2. PBMC were separated by using
Ficoll-Hypaque density gradient centrifugation and were
frozen until use.
Viruses. Dengue virus type 1 (Hawaii strain) and type 2
(New Guinea C strain) were provided by Walter E. Brandt of
the Walter Reed Army Institute of Research. Dengue virus
type 3 (CH53489 strain) was supplied by Bruce I. Innis of the
Armed Forces Research Institute of Medical Science,
Bangkok, Thailand, and dengue virus type 4 (814669 strain)
was obtained from Jack McCown of the Walter Reed Army
Institute of Research. These viruses were propagated in
C6/36 mosquito cells to titers of 107 to 108 PFU/ml as
previously described (21) and stored at -70°C until use.
Dengue virus-vaccinia virus recombinants were obtained
by recombining appropriate cDNA sequences of dengue
virus type 4 strain 814669 with a pSCll vaccinia virus
intermediate vector and transfecting vaccinia virus strain
WR-infected CV-1 cells with this DNA (4, 11, 35). The
resulting recombinant viruses were isolated and plaque
purified twice. Recombinant viruses were propagated in
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CV-1 cells, and titers ranged from 1 x 108 to 5 x 108
PFU/ml. Four recombinants were used in this study: A,
which contains the genes for dengue virus type 4 NS1, NS2a,
NS2b, NS3, NS4a, and 84% of NS4b; B, which includes the
genes for dengue virus type 4 C, pre-M, E, NS1, and NS2a
(35); C, which contains genes for dengue virus type 4 NS1
and NS2a (11); D, which is vaccinia virus containing the lacZ
gene (8) and which was used as a control; and E, which
contains the gene for dengue virus type 4 E protein (4).
Preparation of dengue virus antigens. Dengue virus anti-
gens were prepared as described previously (22). Vero cells
grown in plastic flasks (Becton Dickinson Labware, Oxnard,
Calif.) were inoculated with dengue virus at a multiplicity of
infection of 1 and cultured in minimal essential medium
containing 2% fetal calf serum (GIBCO Laboratories, Grand
Island, N.Y.) until 50% of the cell monolayer exhibited
cytopathic effects. Cells were then scraped from the flasks
with rubber cell scrapers (Costar, Cambridge, Mass.),
washed three times with phosphate-buffered saline at 4°C,
treated with 0.025% glutaraldehyde (Sigma, St. Louis, Mo.)
in phosphate-buffered saline at 4°C for 15 min, washed three
more times with phosphate-buffered saline, and suspended
in RPMI 1640. Cells were then sonicated with a sonic
dismembrator (Fisher Scientific Co., Pittsburgh, Pa.) for 2 to
3 min and were finally centrifuged at 1,600 x g for 10 min.
The supernatants were collected and stored at -70°C until
used. Control antigens were prepared the same way by using
uninfected Vero cells. Fifteen 75-cm2 flasks were used to
prepare 3-ml samples of antigens.
Stimulation of PBMC. A total of 4 x 106 PBMC from a
dengue virus type 4-immune donor were suspended in 1 ml
of RPMI 1640 containing penicillin-streptomycin, glutamine,
HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic
acid) (Sigma), and 10% heat-inactivated pooled human AB
serum (Hazelton Research Products, Inc., Lenexa, Kans.)
and placed into wells of 24-well cluster plates (Costar). One
milliliter of dengue virus containing 107 to 108 PFU was
added to each well, and the plates were incubated for 6 to 9
days at 37°C with 5% CO2 in a humid incubator. Mock
stimulation was carried out by using uninfected mosquito
cell supernatants.
Cell lines. Skin fibroblast cultures were established by
using a 3-mm biopsy sample of skin which was minced. Cells
were passed several times in 75-cm2 flasks before samples
were frozen and later thawed and used as targets. These cells
were maintained in minimal essential medium with 10% fetal
calf serum with the same additives as listed above.
Lymphoblastoid cell lines (LCL) were established by
infecting PBMC with Epstein-Barr virus obtained from an
infected marmoset cell line (29) provided by Takeshi Sairenji
of University of Massachusetts Medical Center. LCL were
maintained in RPMI containing 10% fetal calf serum and the
same additives as listed above.
Infection and antigen pulsation of target cells. A total of 1 x
105 to 2 x 105 fibroblasts were suspended in 100 ,ul of
minimal essential medium in 15-ml conical centrifuge tubes
and mixed with 100 ,ul of virus or uninfected mosquito cell
supernatant and incubated for 1.5 to 2 h at 37°C with
occasional agitation. The cells were then diluted, and 2 ml
was seeded into wells of 24-well cluster plates overnight for
use as target cells the next morning. The multiplicities of
infection used were between 10 and 50 for dengue virus and
between 2 and 5 for the dengue virus-vaccinia virus recom-
binants.
Antigen pulsation was performed after seeding 105LCL or
fibroblasts in 24-well cluster plates in a volume of 0.5 ml.
Soluble dengue virus antigens were added at final dilutions
between 1:20 and 1:200 15 to 18 h before cytotoxicity assays.
In some experiments, beta interferon (Lee Biomolecular,
San Diego, Calif.) was added at a final concentration of 5,000
U/ml 2 to 3 days before antigen pulsation. This has been
shown to render target cells resistant to lysis by NK cells
(31) and to increase their sensitivity to CTL (5).
Cell surface antigen analysis. Anti-Leu2 (CD8) and anti-
Leu3 (CD4) antibodies directly conjugated to fluorescein
isothiocyanate (Becton Dickinson Co., Mountain View,
Calif.) were used to quantitate CD8+ and CD4+ PBMC.
Briefly, 20 ,u1 of antibody was mixed with 105 to 106 cells in
a volume of 50 ,ul and incubated for 45 to 60 min at 4°C. Cells
were then washed twice in cold RPMI 1640 and were then
analyzed on a fluorescence-activated cell sorter (FACS 440;
Becton Dickinson Co.) or by fluorescence microscopy.
Antibody-complement depletion. Anti-OKT4 (CD4) and
anti-OKT8 (CD8) antibodies (Ortho Diagnostic Systems,
Inc., Raritan, N.J.) and anti-Leu llb (CD16; Becton Dick-
inson Co.) were used in antibody-complement depletion
experiments. A total of 1 x 106 to 2 x 106 virus-stimulated
PBMC were suspended in 50 ,ul, and then 100 ,l1 of antibody
diluted 1:15 was added, followed by incubation at 4°C for 30
min. The cells were washed twice in cold RPMI 1640 and
suspended in 100 Pld, to which 200 ,lI of rabbit complement
diluted 1:3 (Cedarlane Laboratories, Ontario, Canada) was
added, followed by incubation for 1 h at 37°C. Cells were
then washed three times in RPMI 1640 and were used in
cytotoxicity assays.
Cytotoxicity assays. A total of 105 to 106 target cells were
labeled with 0.5 mCi of 51Cr (Na2CrO4) (Dupont, NEN
Research Products, Boston, Mass.) in 0.2 ml of RPMI 1640
containing 10% fetal calf serum at 37°C for 1 h. The cells
were then washed three times and suspended at 104 cells per
ml for fibroblasts and 2.5 x 104 cells per ml for LCL and
added to 96-well round-bottomed microdilution plates (Cos-
tar) in a volume of 100 plA in triplicate. Effector cells were
added in a volume of 100 ,ul for a final volume of 200 pl1. After
incubation for 4 to 6 h, the plates were centrifuged at 200 x
g for 5 min, and supernatant fluids were collected and
counted in a gamma counter (Packard, Sterling, Calif.). The
percent specific release was calculated by the formula [(cpm
experimental release) - (cpm spontaneous release)]/[(cpm
maximum release) - (cpm spontaneous release)] x 100, in
which cpm is counts per minute. The spontaneous release of
label was between 11 and 30%. Maximum release was
assessed by treatment of labeled cells with detergent.
Antibody blocking of cytotoxicity. W6/32 (Accurate Chem-
ical and Scientific Co., Westbury, N.Y.) and OKIal (Ortho)
are monoclonal antibodies which recognize framework de-
terminants of human leukocyte antigen A, B, and C, and DR
determinants, respectively. A 50-,ul portion of antibody
diluted 1:20 was added to 50 pI of 51Cr-labeled target cells
(2 x 103 to 5 x 103/ml) in 96-well round-bottomed plates for
10 min, followed by addition of 100 p1 of effector cells. The
assays were 4 h long.
Proliferation assay. A 100-pd sample of cells from 6-
day-old PBMC bulk cultures was added to 96-well microdi-
lution wells in triplicate and pulsed with 1.25 puCi of tritiated
thymidine for 4 to 16 h before harvest. Cells were harvested
by using a Titertek Multiharvester (Skatron, Inc., Sterling,
Va.), and [3H]thymidine incorporation was counted in a
liquid scintillation counter (Packard Instrument Co., Inc.,
Rockville, Md.).
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TABLE 1. Stimulation of dengue virus type 4-immune PBMC
with live and UV-inactivated dengue virus
Expt. Stimulus [3H]thymidine Stimulation
no. (cpm) index
1 Dengue virus type 4 26,712 5.6
Dengue virus type 2 13,137 2.7
Mocka 4,789
2 Dengue virus type 4 19,652 16.0
Dengue virus type 4b 627 0.5
Mocka 1,209
a Uninfected mosquito cell supernatants were used for mock stimulation.
b UV inactivated.
RESULTS
Stimulation of dengue virus type 4-immune PBMC with live
or UV-inactivated dengue virus. PBMC taken from a dengue
virus type 4-immune donor were placed in culture with either
live dengue virus or virus which had been exposed to UV
light and shown to have no plaque-forming capacity. After 6
days, the cells were pulsed with [3H]thymidine, and prolif-
eration was assessed. The results in Table 1 show that the
dengue virus type 4-immune PBMC responded best to den-
gue virus type 4. There was also a lower but significant
response to dengue virus type 2, which indicated that the
response was serotype cross-reactive. Nonimmune PBMC
did not respond (data not shown), and UV-inactivated den-
gue virus type 4 failed to generate a response.
Lysis of dengue virus-infected fibroblasts by dengue virus
type 4-immune PBMC stimulated by live dengue virus. PBMC
from a dengue virus type 4-immune donor were tested for
cytotoxic activity against dengue virus-infected autologous
fibroblasts after 7 to 9 days of stimulation with dengue virus.
Fibroblasts were chosen as target cells to detect CD8+ CTL
because they do not constitutively express class II major
histocompatibility complex antigens (25). Dengue virus type
4-immune PBMC stimulated with either dengue virus type 2
or dengue virus type 4 lysed fibroblasts infected with either
serotype (Table 2). Uninfected cells were also lysed, but the
levels of lysis were always lower than those against virus-
infected targets. These results show that the cytotoxic
response is serotype cross-reactive.
Characterization of cytotoxic activity. Antibody-blocking
and antibody-complement depletion studies were carried out
to determine the identity of the killer cells. Inclusion in the
cytotoxicity assay of an antibody against class I antigens,
W6/32, inhibited the killing of dengue virus type 2-infected
TABLE 2. Lysis of dengue virus-infected fibroblasts by dengue
virus type 4-immune PBMC stimulated with dengue virus
% Specific 51Cr release from fibroblasts
Expt. infected with:EPt* PBMC stimulusno Dengue virus Dengue virus No virus
type 4 type 2 (mock)a
1b Dengue virus type 4 26 26 2
Dengue virus type 2 28 24 7
Mocka 2 5 2
2C Dengue virus type 4 62 58 2
a Uninfected mosquito cell supernatant.
b Effector-to-target ratio was 40:1 in a 4-h assay.
c Effector-to-target ratio was 100:1 in a 4-h assay.
TABLE 3. Characterization of cytotoxic activitya
Expt Dengue virus % Specific 5"Cr release % Inhibi-





anti-CD8 + complement 18 61
anti-CD4 + complement 50 -9
anti-Leu llb + complement 44 4
a Effector-to-target ratio was 100:1 in a 4-h assay.
fibroblasts by 48% (Table 3), which indicates that much of
the killing was class I antigen restricted. An antibody to class
II DR antigens, OKIa-1, inhibited the killing poorly, showing
that the killing was not DR restricted. Since fibroblasts do
not express any class II antigens under these conditions (25),
killing restricted by the other class II antigens (DP and DQ)
can also be excluded.
Treatment of the effector population with anti-CD8 and
complement resulted in the death of 37% of these cells and
reduced their lytic capacity against dengue virus type 2-
infected fibroblasts by 61% (Table 3). Anti-CD4 and comple-
ment treatment similarly killed 35% of the effector popula-
tion but failed to inhibit the cytotoxic activity (Table 3).
Anti-Leu llb and complement treatment failed to induce
either a significant decrease in viability (data not shown) or
a reduction in the cytotoxic capacity of effector cells (Table
3). Taken together, these results indicate that the effector
cells in this system were virus-specific, CD8+, HLA class
I-restricted, serotype-cross-reactive CTL.
Cross-reactive lysis of dengue virus antigen-pulsed LCL and
fibroblasts. It is difficult to infect an adequate percentage of
human LCL and fibroblasts in vitro with dengue virus types
1 and 3; therefore, we pulsed fibroblasts and LCL with
dengue virus antigens prepared from dengue virus-infected,
glutaraldehyde-fixed Vero cells and used them as targets for
dengue virus-stimulated PBMC.
Fibroblasts and LCL pulsed with dengue virus antigens
were efficiently lysed by dengue virus type 4-stimulated
PBMC, but lysis of control antigen-treated or untreated
fibroblasts was minimal (Table 4). Thus, these CTL are
cross-reactive against all four dengue virus serotypes.
We characterized the major histocompatibility complex
restriction of killing against LCL by including antibodies to
class I (W6/32) and class II (OKIa-1) antigens in the cyto-
TABLE 4. Lysis of dengue virus antigen-pulsed
LCL and fibroblastsa
% Specific release of target cells treated with
Target cell antigens from dengue virus type:
type
1 2 3 4 Control'
Fibroblasts 21 56 27 19 5
Fibroblasts NDC ND ND 36 5
LCL ND ND ND 52 7
a Effectors were dengue virus type 4-immune PBMC stimulated for 8 days
with dengue virus type 4. The effector-to-target ratio was 100:1, and the assay
length was 6 h. Target cells pulsed with dengue virus antigens or control
antigens were used as targets the following day.
b Control antigen, Uninfected mosquito cell supernatant.
c ND, Not done.
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TABLE 5. Lysis of fibroblasts infected with dengue virus-
vaccinia virus recombinantsa
% Specific 51Cr
Infecting virus or recombinant release in:
(proteins)
Expt 1 Expt 2
Dengue virus type 2 94 NDb
Dengue virus type 4 72 31
A (NS1, NS2a, NS2b, NS3, NS4a, NS4b) 39 17
B (C, pre-M, E, NS2, NS2a) 8 13
C (NS1, NS2a) -2 0
Vaccinia virus controlc
E (E) 13 28
None (mock infection) -4 -1
a Effectors were from dengue virus type 4-immune PBMC stimulated for 8
days with dengue virus type 4. Assay length was 4 h. Effector-to-target ratio
was 100:1 in experiment 1 and 40:1 in experiment 2.b ND, Not done.
I Lysis of targets infected with vaccinia virus was 12% in both experiments,
which was subtracted for clarity.
toxicity assays. W6/32 inhibited the killing by 57%, whereas
OKIa-1 had no effect. These data and the fact that fibro-
blasts, which lack class II antigens, are killed argue strongly
that this lysis is mediated by class I-restricted CTL.
Lysis of fibroblasts infected with dengue virus-vaccinia virus
recombinants. We examined the proteins which are targets
for dengue virus-specific class I-restricted CTL by infecting
fibroblasts with dengue virus-vaccinia virus recombinant
viruses, each of which contained a different portion of the
dengue virus type 4 genome. Recombinant A contained
genes which code for dengue virus proteins NS1, NS2a,
NS2b, NS3, NS4a, and 84% of NS4b. Recombinant B
contained genes coding for C, pre-M, E, NS1, and NS2a.
Recombinant C included genes coding for NS1 and NS2a,
and recombinant E contained genes coding for the E protein.
Recombinant D is the parental vaccinia virus which contains
the lacZ gene and has none of the dengue virus genome and
served as a control. CTL lysed fibroblasts infected with
recombinants A, B, and E, but not those infected with C and
D (Table 5). These results show that E is a target protein for
these CTL but that NS1 and NS2a are not. The data also
imply that at least one of the NS2b, NS3, NS4a, or NS4b
proteins is a target for these CTL. From these studies, we
cannot determine whether C, pre-M, and NS5 contain target
epitopes for CTL. Recombinant vaccinia viruses which
contained the genes for the dengue virus type 2C, pre-M, and
E proteins and the genes for dengue virus type 2 NS1 and
NS2a proteins were also used to infect autologous fibro-
blasts. Consistent with the concept that these CTL are
cross-reactive, fibroblasts infected with the dengue virus
type 2 recombinant expressing C, pre-M, and E proteins
were lysed by dengue virus type 4-stimulated, dengue virus
type 4-immune PBMC. However, these PBMC did not lyse
fibroblasts infected with the dengue virus type 2 recombinant
expressing NS1 and NS2a (data not shown).
DISCUSSION
In this report, we describe serotype-cross-reactive, CD8+
CD4-, class I-restricted, dengue virus-specific CTL ob-
tained after stimulation with live virus of PBMC from a
dengue virus-immune individual. The evidence that lysis was
mediated by class I-restricted CD8+ CTL is as follows: (i)
antibody and complement treatment of the effectors using
anti-CD8 or anti-CD3 but not anti-CD16 or anti-CD4 de-
pleted the killing (Table 3); (ii) antibody to class I but not
class II antigens decreased the level of lysis (Table 3); (iii)
virus-infected fibroblasts, which do not express major histo-
compatibility complex class II antigens (25), were specifi-
cally lysed (Tables 2, 4, and 5). In other viral systems (2, 16),
the use of live virus or virus-infected fibroblasts has also
been necessary to induce class I-restricted CD8+ CTL. This
may be due to the requirement for intracellular antigen
synthesis sometimes required for optimal presentation of
antigen in the context of class I molecules (17, 26, 33).
Stimulation of PBMC with soluble dengue virus antigens
generated CD4+ class II-restricted CTL (22a). We failed to
induce CD8+ CTL with soluble dengue virus antigens de-
spite inducing good levels of proliferation.
However, fibroblasts and LCL pulsed with these antigens
were sensitive to class I-restricted CTL-mediated lysis. This
appears to be consistent with a report which showed that
influenza virus proteins could bind to class I antigens dis-
played on the plasma membrane and that these antigen-
pulsed targets were sensitive to lysis by influenza virus-
specific, CD8+, class I-restricted CTL (32).
A rather large amount of dengue virus was necessary for
optimal CTL induction (107 to 108 PFU). During secondary
dengue virus infections, the increased amount of virus
present due to antibody-mediated enhancement of infection
in Fc receptor-positive cells and the presence of memory
CTL may result in a more vigorous CTL response than is
usually present during primary infections. This CTL re-
sponse may contribute both to the enhanced destruction of
virus-infected cells and to immunopathology. Although
DHF-DSS are more commonly observed during secondary
dengue virus infections, some infants 6 to 12 months of age
with maternally derived enhancing antibodies develop DHF-
DSS during primary dengue virus infections (13). This may
be triggered by a primary CTL response against an aug-
mented number of infected monocytes.
In order to postulate that CTL play a role in viral clear-
ance and DHF-DSS during secondary dengue virus infec-
tions, they must be serotype cross-reactive with regard to
specificity for induction and lysis. Stimulation by dengue
virus type 2 of PBMC from a dengue virus type 4-immune
individual induced proliferation of CTL capable of lysing
dengue virus type 2-infected targets (Tables 1 and 2). Stim-
ulation of these PBMC with dengue virus type 4 resulted in
CTL capable of lysing target cells expressing all four sero-
types of dengue virus (Table 4), thus demonstrating the
cross-reactive nature of these CTL.
Our bulk culture studies revealed the presence of cross-
reactive CTL. We have recently isolated 12 CD8+ CD4-
CD16- CTL clones from a dengue virus type 4-immune
individual which were capable of lysing dengue virus type
2-infected targets (unpublished data), demonstrating cross-
reactivity at the clonal level. We have also described clones
of serotype-cross-reactive, class II-restricted, CD4+ CD8-
CTL, using soluble dengue virus antigens as a stimulus (22a).
These clones proliferated and produced IFN--y in response to
soluble antigens from all four serotypes. It will be useful to
compare class I- and class II-restricted clones with regard to
fine specificity and lymphokine production in order to better
understand their roles in recovery from dengue virus infec-
tion and in the pathogenesis of DHF-DSS.
DHF-DSS is usually observed in individuals undergoing a
secondary infection with a different serotype of dengue virus
than that which caused the primary infection. Thus, it is
likely that cross-reactive immune responses are responsible
for the pathogenesis of DHF-DSS. T cells may be involved
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in several ways. Production of IFN-y (22, 22a) by CD4+
CTL leads to an increase in Fc receptor expression on
monocytes (12), which results in a greater number of in-
fected monocytes by virus-antibody complexes (19). These
monocytes may then be susceptible to lysis by class I- and
class II-restricted CTL, resulting in the release of vasoactive
factors such as complement components (3) and tumor
necrosis factor (10). T cells may also play a role in DHF-DSS
by producing interleukin 2. Interleukin 2 augments NK cell
activity and proliferation (30). NK cells can mediate ADCC
(21) and produce IFN-y as well as tumor necrosis factor (10,
30), which may further contribute to DHF-DSS (1).
Currently there is no effective vaccine against dengue
virus. In order to design a safe and effective vaccine and to
understand the pathogenesis of DSS, it is important to learn
which dengue virus-coded proteins induce protective T-cell
responses and which responses may lead to DHF-DSS. Our
studies using dengue virus type 4-vaccinia virus constructs
indicate that the E protein and one or more of the NS2b,
NS3, NS4a, and NS4b proteins are targets for CD8+ CTL.
Since the E protein also contains epitopes for cross-reactive
antibodies which can mediate immune enhancement (14),
there is concern about using it in a vaccine. NS proteins are
not expressed in virions and may be candidates for use in a
subunit vaccine. It is therefore important to elucidate which
NS proteins are recognized by cross-reactive T cells and
which NS proteins are targets for CTL-mediated clearance
and/or CTL-mediated DHF-DSS.
NS1 or NS2a do not seem to contain CTL epitopes in this
system, despite the facts that NS1 is a highly conserved
protein among all four dengue virus serotypes and that it
induces a serotype cross-reactive antibody response (28).
Immunization of mice with NS1 protein protects mice
against intracerebral challenge with dengue virus, but the
protection is not serotype cross-reactive (28). Recently, one
of us reported that immunization with a cell lysate containing
dengue virus proteins C, pre-M, E, NS-1, and NS2a pro-
tected mice against dengue virus encephalitis (34). Mice
immunized with this preparation develop antibody responses
to NS1 but lack consistently detectable virus neutralizing
antibodies. Mice immunized with a dengue virus-vaccinia
virus recombinant containing the gene for dengue virus type
4 E protein also resisted a fatal challenge with dengue virus
type 4; anti-dengue virus antibody titers were either low or
undetectable in these mice (4). Cell-mediated immune re-
sponses were not analyzed in those experiments, and the
mechanism of protection remains speculative.
Further studies are needed to better define the proteins
and epitopes which are recognized by dengue virus-specific
CTL and their major histocompatibility complex haplotype
restrictions. This information could be important in deter-
mining which elements of the CTL response contribute to
recovery from dengue virus infection and to the severe
complications of dengue virus infections.
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